Where it trades today
trading 59% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ZBH is valued near its sector range at 23.1x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- Recent realized volatility is running around 27.6%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ZBH is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ZBH.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ZBH come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ZBH. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Zimmer Biomet does
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for…
What analysts expect
ZBH carries a buy consensus from 21 analysts, with an average price target of $107.57 versus $95.36 today (+12.8%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ZBH generated $8.51B in trailing revenue (4.8% year over year), with a 9.5% net margin, and $1.07B of free cash flow, against $7.14B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $8.23B | $5.74B | $1.36B | $705.10M | $3.56 | $1.42B |
| 2024 | $7.68B | $5.49B | $1.53B | $903.80M | $4.45 | $1.14B |
| 2023 | $7.39B | $5.31B | $1.45B | $1.02B | $4.91 | $1.19B |
| 2022 | $6.94B | $4.92B | $1.19B | $231.40M | $1.10 | $1.07B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ZBH beside the healthcare names it is usually measured against.
What the chart is saying
Zimmer Biomet trades at $95.36, 10.8% below its 52-week high. With a beta of 0.47, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is ZBH a good buy right now?
Zimmer Biomet trades at 23.1x earnings. This is near market average. Current risk level is Medium based on 27.6% volatility.
Does ZBH pay dividends?
Yes, Zimmer Biomet offers a dividend yield of 1.02%. That is roughly $0.97 per share a year.
How volatile is ZBH?
With 30-day annualized volatility of 27.6% and beta of 0.47, ZBH is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for ZBH?
The average analyst price target for Zimmer Biomet (ZBH) is $107.57 based on 21 analyst estimates, about 12.8% above the current price of $95.36. The published range runs from $93.00 to $130.00.
How much revenue does ZBH generate?
Zimmer Biomet reported $8.51B in trailing twelve-month revenue. Revenue growth is running at 4.8% year over year. Net margin sits at 9.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.